Physician profile
Maria Lufrano
NPI 1639326424
$5,979.73
in general payments reported to CMS, 2019-2025
26 companies · $1,660 in 2025
The $1,660 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15.48 · 2020: $133 · 2021: $168 · 2022: $605 · 2023: $1,202 · 2024: $2,196 · 2025: $1,660.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,059.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,058.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,129.34 | 2020-2025 | Xifaxan, Trulance |
| Celgene Corporation | $606.50 | 2021-2024 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $571.31 | 2023-2025 | Entyvio |
| Abbvie INC. | $508.29 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $446.50 | 2023-2024 | Zeposia |
| Phathom Pharmaceuticals, INC. | $383.86 | 2023-2025 | Voquezna |
| Qol Medical, LLC | $382.30 | 2022-2025 | Sucraid, Sucraid |
| Madrigal Pharmaceuticals | $335.26 | 2024-2025 | Rezdiffra, Resmetirom |
| Pfizer INC. | $327.97 | 2023-2025 | |
| Novo Nordisk INC | $229.27 | 2024-2025 | Wegovy, Saxenda |
| Ironwood Pharmaceuticals, INC | $182.70 | 2022-2024 | Linzess |
| Ardelyx, INC. | $179.44 | 2022-2025 | Ibsrela |
| Intercept Pharmaceuticals, INC. | $156.25 | 2023-2025 | Ocaliva |
| Celltrion USA INC. | $107.43 | 2024 | Vegzelma |
| Janssen Pharmaceuticals, INC | $105.33 | 2020 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $53.80 | 2025 | Cologuard Collection Kit |
| Aimmune Therapeutics, INC. | $48.88 | 2025 | Zenpep |
| Olympus America INC. | $48.09 | 2025 | Endoclot Phs |
| Evoke Pharma, INC. | $37.18 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $32.51 | 2025 | Dupixent |
| Organon LLC | $23.48 | 2024 | |
| W. L. Gore & Associates, INC. | $21.57 | 2022 | |
| Braintree Laboratories, INC. | $18.71 | 2022 | |
| Alfasigma USA, INC. | $17.86 | 2022 | |
| Redhill Biopharma INC. | $14.63 | 2020 | |
| Gilead Sciences, INC. | $11.27 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maria Lufrano listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.